Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs is proud to offer a wide range of CD79A CART-related products, such as CAR viral particles and CAR cells.
CD79a has been recognized as a particular antigen exclusive to B cells, and its expression commences during the early stages of pre-B cell formation and continues throughout B cell differentiation until reaching the plasma cell stage. This antigen, known as CD79a, holds significant importance as a crucial marker utilized in regular immunophenotypic analysis. According to studies, CD79a demonstrates a remarkable specificity of 88% and an outstanding sensitivity of 100% for B-cell differentiation.
Our extensive selection of CD79A protein and cell products are commonly employed for evaluating the expression of anti-CD79A CAR-T cells. This includes:
CD79A CAR-T Cytokine Release Test
CD79A CAR-T Cytokine Release Test service is a comprehensive offering that enables the accurate measurement and analysis of cytokine release in response to CD79A CART. This service utilizes advanced laboratory techniques and assays to measure the levels of various cytokines, including interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).
Fig.1 CAR T-cell IL-2 or IFN-γ production measured by ELISA.1
CD79A CAR-T In Vitro Cytotoxicity Assay
We offer a comprehensive and reliable solution that provides researchers with a valuable tool for evaluating the effectiveness of CD79A CART. The assay also enables the evaluation of CD79A CAR-T cell activity by measuring various functional readouts. These readouts include target cell viability and apoptosis induction. Target cell viability can be assessed using various methods such as cell counting and MTT assay.
CD79A CAR-T Cell Proliferation Test
CD79A CAR-T Cell proliferation test is a cutting-edge and comprehensive service offered by our company. This test is specifically designed to measure the proliferation and expansion of CD79A CAR-T cells in response to different stimuli.
CD79A CAR-T Cell Therapy Animal Models
To facilitate the development and optimization of CD79A CAR-T cell therapy, animal models play a crucial role in preclinical studies. Creative Biolabs offers comprehensive animal model services to support the evaluation and efficacy testing of CD79A CAR-T cell therapy.
Fig.2 Representative flow cytometric analysis of T cells and tumor cells in bone marrow from tumor bearing mice.1
The efficacy test of CD79A CAR-T is a vital step in assessing the effectiveness and potential therapeutic benefits of this innovative treatment. The efficacy test aims to evaluate the ability of CD79A CAR-T cells to effectively recognize and destroy cancer cells expressing CD79A. This test is performed in vivo to comprehensively assess the treatment's efficacy on multiple levels.
Survival of mice
Fig.3 Survival of mice from 2 independent experiments.1
Toxicity Evaluation of CD79A CAR-T
The toxicity evaluation service at Creative Biolabs includes several assessments to comprehensively evaluate the safety profile of CD79A CAR-T cells using animal models. This includes monitoring the general health status, body weight, and any signs of distress or adverse reactions.
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-1122-YF220 | Anti-CD79A KIR CAR (scFv-KIR2DS2-DAP12, XW-220), pCDCAR1 | Human | XW-220 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
| XS-1122-YF221 | Anti-CD79A KIR CAR (scFv-KIR2DS2-DAP12, XW-221), pCDCAR1 | Human | XW-221 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
| XS-1122-YF222 | Anti-CD79A KIR CAR (scFv-KIR2DS2-DAP12, XW-222), pCDCAR1 | Human | XW-222 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
| XS-1122-YF223 | Anti-CD79A KIR CAR (scFv-KIR2DS2-DAP12, XW-223), pCDCAR1 | Mouse | XW-223 | Rat | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
| XS-1122-YF1140 | Anti-CD79A TCR-ABR (scFv-TCRα, XW-220) CAR Plasmid, pCDCAR1 | Human | XW-220 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
| XS-1122-YF1141 | Anti-CD79A TCR-ABR (scFv-TCRα, XW-221) CAR Plasmid, pCDCAR1 | Human | XW-221 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
| XS-1122-YF1142 | Anti-CD79A TCR-ABR (scFv-TCRα, XW-222) CAR Plasmid, pCDCAR1 | Human | XW-222 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
| XS-1122-YF1143 | Anti-CD79A TCR-ABR (scFv-TCRα, XW-223) CAR Plasmid, pCDCAR1 | Mouse | XW-223 | Rat | scFv-TCRα | Lentiviral vector | T Cell | ||
| XS-1122-YF2060 | Anti-CD79A TCR-ABR (scFv-TCRβ, XW-220) CAR Plasmid, pCDCAR1 | Human | XW-220 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
| XS-1122-YF2061 | Anti-CD79A TCR-ABR (scFv-TCRβ, XW-221) CAR Plasmid, pCDCAR1 | Human | XW-221 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
| XS-1122-YF2062 | Anti-CD79A TCR-ABR (scFv-TCRβ, XW-222) CAR Plasmid, pCDCAR1 | Human | XW-222 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
| XS-1122-YF2063 | Anti-CD79A TCR-ABR (scFv-TCRβ, XW-223) CAR Plasmid, pCDCAR1 | Mouse | XW-223 | Rat | scFv-TCRβ | Lentiviral vector | T Cell | ||
| XS-1122-YF2980 | Anti-CD79A TCR-ABR (scFv-CD3γ, XW-220) CAR Plasmid, pCDCAR1 | Human | XW-220 | Mouse | scFv-CD3γ | Lentiviral vector | T Cell | ||
| XS-1122-YF2981 | Anti-CD79A TCR-ABR (scFv-CD3γ, XW-221) CAR Plasmid, pCDCAR1 | Human | XW-221 | Mouse | scFv-CD3γ | Lentiviral vector | T Cell | ||
| XS-1122-YF2982 | Anti-CD79A TCR-ABR (scFv-CD3γ, XW-222) CAR Plasmid, pCDCAR1 | Human | XW-222 | Mouse | scFv-CD3γ | Lentiviral vector | T Cell | ||
| XS-1122-YF2983 | Anti-CD79A TCR-ABR (scFv-CD3γ, XW-223) CAR Plasmid, pCDCAR1 | Mouse | XW-223 | Rat | scFv-CD3γ | Lentiviral vector | T Cell | ||
| XS-1122-YF3900 | Anti-CD79A TCR-ABR (scFv-CD3δ, XW-220) CAR Plasmid, pCDCAR1 | Human | XW-220 | Mouse | scFv-CD3δ | Lentiviral vector | T Cell | ||
| XS-1122-YF3901 | Anti-CD79A TCR-ABR (scFv-CD3δ, XW-221) CAR Plasmid, pCDCAR1 | Human | XW-221 | Mouse | scFv-CD3δ | Lentiviral vector | T Cell | ||
| XS-1122-YF3902 | Anti-CD79A TCR-ABR (scFv-CD3δ, XW-222) CAR Plasmid, pCDCAR1 | Human | XW-222 | Mouse | scFv-CD3δ | Lentiviral vector | T Cell | ||
| XS-1122-YF3903 | Anti-CD79A TCR-ABR (scFv-CD3δ, XW-223) CAR Plasmid, pCDCAR1 | Mouse | XW-223 | Rat | scFv-CD3δ | Lentiviral vector | T Cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
